City

Harbin (1)

Condition

ALK Phosphorylation (1)

Overall Status

Completed (1)

Sign in for free

Phase

n/a (1)

Sponsor

Harbin Medical University (1)

Collaborator

Intervention

crizotinib for rearrangement-negative, high phosphorylated alk patients (1)

Study Documents

Intervention Type

drug (1)

Funder Type

Other (1)

Study Type

Interventional (1)

alk phosphorylation

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

ALK Phosphorylation Trial in Harbin (crizotinib for rearrangement-negative, high phosphorylated ALK patients)

Completed

ALK Phosphorylation

crizotinib for rearrangement-negative, high phosphorylated ALK patients

Harbin, Heilongjiang, China

Harbin Medical University Cancer Hospital

Mar 19, 2023